JCP

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
[Advanced]

Journal of Clinical Pathology 2006;59:984-987; doi:10.1136/jcp.2005.035394
Copyright © 2006 by the BMJ Publishing Group Ltd & Association of Clinical Pathologists.

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Add article to my folders
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mian, C
Right arrow Articles by Pycha, A
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mian, C
Right arrow Articles by Pycha, A
Right arrowPubmed/NCBI databases
Medline Plus Health Information
*Bladder Cancer

ORIGINAL ARTICLE

Multiprobe fluorescence in situ hybridisation: prognostic perspectives in superficial bladder cancer

C Mian1, M Lodde2, E Comploj2, L Lusuardi2, S Palermo2, M Mian2, K Maier1, A Pycha2

1 Department of Pathology, Central Hospital of Bolzano, Bolzano, Italy
2 Department of Urology, Central Hospital of Bolzano

Correspondence to:
C Mian
Department of Pathology, Central Hospital of Bolzano,L. Boehler St 5, I-39100 Bolzano, Italy;chmian{at}libero.it Aim: To establish independent prognostic factors on a chromosomal basis in superficial bladder cancer, using a multicolour fluorescence in situ hybridisation (FISH) probe mix.

Patients and methods: In 2002, voided urine from 75 consecutive patients (mean age 71.7, range 52–93) years under follow-up for superficial urothelial cancer was studied prospectively. The patients were observed for a mean (standard deviation (SD)) period of 39.3 (6.8) months (range 27–58) until July 2005. A multicolour FISH on liquid-based voided urinary cytology was carried out on all patients. Univariate analysis, using a log rank test, was used to determine the prognostic relevance of a low-risk pattern and a high-risk pattern. Progression-free survival time was calculated from the date of first diagnosis to first recurrence or progression according to the Kaplan–Meier product-limit method.

Results: One patient was lost to follow-up. 27 of the 74 remaining (36.8%) patients showed recurrent disease. In 9 (33.3%) patients with a low-risk pattern disease recurred after a mean (SD) observation time of 29.7 (1.9) months (range 8.3–52.3, median 30.8 (12.4)). 18 (66.7%) patients with a high-risk pattern developed recurrence within a mean (SD) of 17.6 (2.0) months (range 4–38.8, median 16.7 (11.6)). The Kaplan–Meier curve for progression-free survival showed marked differences between the low-risk and the high-risk groups.

Conclusion: Patients with a high-risk chromosomal pattern have a markedly shorter disease-free survival time and higher progression rate than patients with a low-risk pattern. High-risk patients can therefore be treated more aggressively to prevent tumour spreading.


Abbreviations: Cis, carcinoma in situ; FISH, fluorescence in situ hybridisation; SSC, sodium saline citrate







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
Journal of Clinical Pathology Molecular Pathology
Terms and conditions relating to subscriptions purchased online  ¦  Website terms and conditions  ¦  Privacy policy
Copyright © 2006 by the BMJ Publishing Group Ltd & Association of Clinical Pathologists.